(2) reporting a serious, unstable psychiatric condition (e.g., bipolar disorder, schizophrenia), (3) reporting a serious, unstable physical health condition that would increase risk of study participation determined by medical history interview and review by study physician (e.g., past or present cardiac problems, respiratory problems, overnight hospitalization in the past 3 months), (4) current criteria for DSM-5 moderate or severe cannabis use disorder, (5) current use of other psychoactive substances confirmed by urine drug screening, unless prescribed and stable for 2 months, (6) living with someone who currently smokes menthol cigarettes, to reduce access to preferred cigarettes during the switching phase of the study, consistent with our pilot [19], (7) known allergy to PG/VG in e-liquid, (8) female participants will be excluded if they are currently pregnant, planning to become pregnant, breastfeeding, or unwilling to use an effective method of birth control for the duration of the study, (9) abnormal spirometry test, (10) if reporting recent cannabis vaping (past 90 days), additional exclusion will be any report of mild or greater EVALI-related symptoms (e.g., cough, shortness of breath, chest pain) without non-EVALI reasonable and proximal cause
Delgado Ziga holds an MFA from Columbia University and has been awarded the Rema Hort Mann Emerging Artist Grant, the Rema Hort Mann Artist Community Engagement Grant, and the Robert Gamblin Fellowship
This article offers a non-promotional, educational overview of the Mevius Light 8mg variant
Choose YITO PACK for Your Customized Cellulose Cigarette Film At YITO PACK, we provide a range of biodegradable products
